Search

Your search keyword '"Elina Ortisi"' showing total 2 results
Start Over Author "Elina Ortisi" Journal international journal of molecular sciences
2 results on '"Elina Ortisi"'

1. TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy

Author

Vincenza Bonfiglio, Chiara Bianca Maria Platania, Francesca Lazzara, Federica Conti, Corrado Pizzo, Michele Reibaldi, Andrea Russo, Matteo Fallico, Elina Ortisi, Francesco Pignatelli, Antonio Longo, Teresio Avitabile, Filippo Drago, and Claudio Bucolo

Subjects
diabetic retinopathy, serum biomarkers, anti-VEGFA, TGFβ, Biology (General), QH301-705.5, Chemistry, QD1-999
Abstract

Transforming growth factor β1 (TGFβ1) is a proinflammatory cytokine that has been implicated in the pathogenesis of diabetic retinopathy (DR), particularly in the late phase of disease. The aim of the present study was to validate serum TGFβ1 as a diagnostic and prognostic biomarker of DR stages. Thirty-eight subjects were enrolled and, after diagnosis and evaluation of inclusion and exclusion criteria, were assigned to six groups: (1) healthy age-matched control, (2) diabetic without DR, (3) non-proliferative diabetic retinopathy (NPDR) naïve to treatment, (4) NPDR treated with intravitreal (IVT) aflibercept, (5) proliferative diabetic retinopathy (PDR) naïve to treatment and (6) PDR treated with IVT aflibercept. Serum levels of vascular endothelial growth factor A (VEGF-A), placental growth factor (PlGF) and TGFβ1 were measured by means of enzyme-linked immunosorbent assay (ELISA). Foveal macular thickness (FMT) in enrolled subjects was evaluated by means of structural-optical coherence tomography (S-OCT). VEGF-A serum levels decreased in NPDR and PDR patients treated with aflibercept, compared to naïve DR patients. PlGF serum levels were modulated only in aflibercept-treated NPDR patients. Particularly, TGFβ1 serum levels were predictive of disease progression from NPDR to PDR. A Multivariate ANOVA analysis (M-ANOVA) was also carried out to assess the effects of fixed factors on glycated hemoglobin (HbA1c) levels, TGFβ1, and diabetes duration. In conclusion, our data have strengthened the hypothesis that TGFβ1 would be a biomarker and pharmacological target of diabetic retinopathy.

Published
2020
Full Text
View/download PDF

2. TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy

Author

Filippo Drago, Vincenza Bonfiglio, Chiara Bianca Maria Platania, Antonio Longo, Federica Conti, Matteo Fallico, Michele Reibaldi, Teresio Avitabile, Andrea Russo, Claudio Bucolo, Elina Ortisi, Corrado Pizzo, Francesco Pignatelli, Francesca Lazzara, Bonfiglio V., Platania C.B.M., Lazzara F., Conti F., Pizzo C., Reibaldi M., Russo A., Fallico M., Ortisi E., Pignatelli F., Longo A., Avitabile T., Drago F., and Bucolo C.

Subjects
0301 basic medicine, Placental growth factor, Male, Vascular Endothelial Growth Factor A, serum biomarkers, Gastroenterology, lcsh:Chemistry, Pathogenesis, chemistry.chemical_compound, 0302 clinical medicine, Transforming Growth Factor beta, Medicine, Molecular Targeted Therapy, lcsh:QH301-705.5, Spectroscopy, Aflibercept, Aged, 80 and over, General Medicine, Diabetic retinopathy, TGF, Computer Science Applications, Vascular endothelial growth factor A, Biomarker (medicine), Intercellular Signaling Peptides and Proteins, Female, Tomography, Optical Coherence, medicine.drug, medicine.medical_specialty, anti-VEGFA, Anti-VEGFA, Serum biomarkers, Catalysis, Article, Proinflammatory cytokine, Inorganic Chemistry, 03 medical and health sciences, TGFβ, Internal medicine, Humans, Physical and Theoretical Chemistry, Molecular Biology, Aged, Diabetic Retinopathy, business.industry, Organic Chemistry, medicine.disease, eye diseases, 030104 developmental biology, lcsh:Biology (General), lcsh:QD1-999, chemistry, Diabetes Mellitus, Type 2, ROC Curve, 030221 ophthalmology & optometry, Glycated hemoglobin, business, Biomarkers
Abstract

Transforming growth factor &beta, 1 (TGF&beta, 1) is a proinflammatory cytokine that has been implicated in the pathogenesis of diabetic retinopathy (DR), particularly in the late phase of disease. The aim of the present study was to validate serum TGF&beta, 1 as a diagnostic and prognostic biomarker of DR stages. Thirty-eight subjects were enrolled and, after diagnosis and evaluation of inclusion and exclusion criteria, were assigned to six groups: (1) healthy age-matched control, (2) diabetic without DR, (3) non-proliferative diabetic retinopathy (NPDR) na&iuml, ve to treatment, (4) NPDR treated with intravitreal (IVT) aflibercept, (5) proliferative diabetic retinopathy (PDR) na&iuml, ve to treatment and (6) PDR treated with IVT aflibercept. Serum levels of vascular endothelial growth factor A (VEGF-A), placental growth factor (PlGF) and TGF&beta, 1 were measured by means of enzyme-linked immunosorbent assay (ELISA). Foveal macular thickness (FMT) in enrolled subjects was evaluated by means of structural-optical coherence tomography (S-OCT). VEGF-A serum levels decreased in NPDR and PDR patients treated with aflibercept, compared to na&iuml, ve DR patients. PlGF serum levels were modulated only in aflibercept-treated NPDR patients. Particularly, TGF&beta, 1 serum levels were predictive of disease progression from NPDR to PDR. A Multivariate ANOVA analysis (M-ANOVA) was also carried out to assess the effects of fixed factors on glycated hemoglobin (HbA1c) levels, TGF&beta, 1, and diabetes duration. In conclusion, our data have strengthened the hypothesis that TGF&beta, 1 would be a biomarker and pharmacological target of diabetic retinopathy.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results